ERBB2 and ovarian carcinoma: Meanwhile, the co-administration of HER2-targeted therapy and carboplatin/paclitaxel chemotherapy contributed to a significant tumor regression after 6 weeks in comparison with single chemotherapy, suggesting that HER2-targeted therapy sensitized ovarian cancer response to chemotherapy of carboplatin and paclitaxel 27.